Interleukin-2 (IL-2) with or without adoptively transferred Previous reports have demonstrated granulocytelymphokine activated killer (LAK) cells has been used in macrophage colony-stimulating factor (GM-CSF)-several trials in an attempt to induce a graft-versus-leukemediated enhancement of lymphokine activated killer mia effect and to reduce the relapse rate after autologous (LAK) cell function. Based on these studies we have bone marrow or peripheral blood stem cell (PBSC) transdeveloped a model of LAK cell generation from perplantation. [1][2][3] The cytolytic ability of LAK cells against ipheral blood stem cells (PBSC) from cancer patients by in vitro incubation with low-dose interleukin-2 (ILseveral hematological and non-hematological malignancies 2) + GM-CSF. PBSC from seven patients were incuhas been demonstrated in vitro, 4,5 and there are some studbated for 48 h at 37؇C in serum-free culture medium ies suggesting an effective antileukemic potential mediated supplemented with IL-2 at increasing concentrations by LAK cells induced in vivo after IL-2 infusion. 3 Unfortu-(10, 100 or 1000 IU/ml) in the presence or absence of nately, IL-2 responsive precursors in vivo are not present 10 IU/ml GM-CSF. LAK activity generated in cultures immediately after transplant when the immunotherapeutic with 10 IU/ml IL-2 + GM-CSF was significantly higher approach could be more effective, 6,7 and it seems that the than that generated by 10 IU/ml IL-2 and did not differ infusion of in vitro activated bone marrow or PBSC in from LAK generation at optimal concentrations of ILaddition to IL-2 therapy could be advantageous.
Materials and methods
In a second experiment, PBSC from five additional patients (PN 8 to 12) were divided into four aliquots and depleted of CD4 + T cells, CD8 + T cells, both CD4 + and Patients and peripheral blood stem cells CD8 + subsets and no depletion, respectively. T cell PBSC samples were obtained from 12 patients and used for depletions were carried out by incubation of the monoexperimental purposes in a preclinical phase. The characternuclear cells with magnetic microspheres coated with antiistics of the patients are shown in Table 1 (PN 1 to 12). In CD4 or anti-CD8 monoclonal antibodies (Dynal, Oslo, a second phase, six patients (PN 13 to 18) received their Norway) for 30 min at 4°C followed by removal of the in vitro activated PBSC as part of a clinical pilot study rosetted cells in a magnetic field. The efficacy of the described later.
depletions was verified by flow cytometry. After T cell All patients underwent leukaphereses after mobilization depletion, cells were cultured in the same conditions as with granulocyte colony-stimulating factor at a dose of above. 10 g/kg/day for 5 days. Aphereses were carried out in a Fenwall CS-3000 Plus blood cell separator (Baxter Health Care, Deerfield, IL, USA), and PBSC were immediately Cytotoxicity assay frozen and cryopreserved in 10% DMSO containing K562 and U937 lines were used respectively as target cells medium. After a variable period of time, PBSC were for NK and LAK assays. Target cells (10 6 /ml) were incuthawed in a water bath and washed twice in RPMI 1640 bated with 1 mCi of sodium 51 CrO 4 for 1 h. After washing added with 5 g/ml of DNAse (Sigma, St Louis, MO, three times, 10 4 labelled cells in 50 l were used as targets USA) and 20 units/ml of preservative-free heparin. Washed in a cytotoxicity assay. The cytotoxicity assay was perforcells were resuspended in a serum-free culture medium Xmed in triplicate in 96 U-round-bottomed well plates. For VIVO 20 (BioWhittaker, Walkersville, MD, USA) at a final spontaneous and total release, samples of target cells were concentration of 3 × 10 7 cells/ml. resuspended in culture medium and 10% triton X-100 (final volume 150 l) respectively. Cells were incubated for 4 h Experimental LAK cell generation for NK assay and for 24 h for LAK assay, at 37°C in 5% CO 2 . Supernatants (100 l) were then collected and coun-PBSC from the first seven patients (PN 1 to 7) were culted in a gamma counter (Ultragamma LKB, Bromma, tured in X-VIVO 20 supplemented with human recombiSweden). Specific lysis was determined with the follownant IL-2 (Eurocetus, Amsterdam, The Netherlands) at proing equation: gressive concentrations (10, 100 and 1000 international units (IU)/ml) in the presence or absence of human recom-% lysis = (problem c.p.m. − spontaneous c.p.m.) (total c.p.m. − spontaneous c.p.m.) × 100 binant GM-CSF (Schering-Plough, Kenilworth, NJ, USA) at fixed concentration of 10 IU/ml. Cell cultures were incubated in flat-bottomed 24-well plates at 37°C for 48 h in a humidified atmosphere of 5% CO 2 in air. After incubation, Clonogenic assay cells were harvested and tested for recovery, viability, cytotoxic activity and myeloid clonogenic potential.
The CFU-GM progenitor cell assay was performed in semisolid medium consisting of Iscove's modified Dulbecco's medium (IMDM; Sigma), 0.9% methylcellulose, 20% fetal received autologous bone marrow. On day +1 and +8 all NHL = non-Hodgkin's lymphoma; AML = acute non-lymphoblastic leupatients received their LAK cells generated in vitro.
kema; ALL = acute lymphoblastic leukemia; CR = complete remission; Breast Ca = breast carcinoma.
For clinical scale LAK cell generation, bags containing PBSC were thawed, washed and resuspended in X-VIVO Results 20 as in previous experiments. Cellular suspensions were transferred to Lifecell culture bags, 300 cm 2 (Baxter Generation of cytotoxic activity Healthcare, Deerfield, IL, USA) and incubated for 48 h in X-VIVO 20 with 10 IU/ml IL-2 plus 10 IU/ml GM-CSF When cultures were stimulated with IL-2 exclusively, genadded. After incubation, activated cells were washed in 1% eration of LAK activity depended on the IL-2 concenhuman serum albumin prior to the infusion into the patients.
tration: at low IL-2 concentration (10 IU/ml) the mean per-GM-CSF was administered to every patient at a dose of centage of lysis was significantly lower than that obtained 5 g/kg/day (i.v.) from day 0 until neutrophils recovered at higher concentrations (100 and 1000 IU/ml) (31.7 ± 3.9 to Ͼ1000 × 10 6 /l for 3 consecutive days. By this time, vs 52 ± 1.5 and 53.4 ± 1.8 respectively; P = 0.01) (see the dose of GM-CSF was reduced to 1 g/kg/day, Figure 1a ). However, when cultures were stimulated with and IL-2 administration was started at 2 × 10 5 IU/m 2 /day IL-2 at low concentration (10 IU/ml) in combination with subcutaneously.
GM-CSF, the LAK activity generated was equivalent to Peripheral blood samples from all patients were taken that obtained with optimal concentrations of IL-2 alone for cytotoxic assays on days 0, +2, +9 and weekly thereafter (51.4 ± 3.3 vs 53.4 ± 1.8; P = NS). In contrast, GM-CSF until day +60. By this time, all six patients were still receivfailed to increase the generation of LAK activity when ing GM-CSF and IL-2 at the above mentioned doses.
added to the cultures stimulated with 100 and 1000 IU/ml of IL-2 (55.8 ± 2.1 vs 52 ± 1.5 and 48 ± 8.6 vs 53.4 ± 1.8 respectively; P = NS) (see Figure 1a) . Regarding the NK activity, cultures stimulated with Flow cytometry 10 IU/ml IL-2 plus GM-CSF showed a mean percentage of lysis higher than those stimulated with 10 IU/ml IL-2, but To assess the efficacy of CD4 + and CD8 + T cell depletion these differences were not statistically significant we used the FITC-labelled antibodies: CD4, CD8 (Coulter (34.2 ± 1.5 vs 42 ± 2.2; P = 0.07) (see Figure 1b) . NK Cyto-Stat) gating on the lymphocyte population. activity was not affected by the addition of GM-CSF to the Surface markers of the infused cells were determined by cultures containing 100 or 1000 IU/IL-2. direct immunofluorescence using the following FITC or phycoerythrin-labelled antibodies: CD2, CD33 (Coulter Cyto-Stat), CD3, CD19, CD14, CD16, CD56, CD25, HLADr (Immunotech, Marseille, France) and CD34 + HPCA-2 Cell viability and clonogenic potential (Becton-Dickinson, San José, CA, USA). Cells were analyzed using an Epics Profile cytometer (Coulter, Hialeah, Cell viability was not negatively influenced by the presence FL, USA) gating on lymphocyte and monocyte populations.
of IL-2 in the cultures at any concentration with respect to the control culture with medium alone. Moreover, low concentration of IL-2 (10 IU/ml) with or without GM-CSF slightly improved cell viability after culture (see Figure 2a ).
Statistical analysis
Regarding the myeloid clonogenic potential, we did not find any significant difference between cultures at different Mean comparisons were made using Wilcoxon's matched concentrations of IL-2, nor in the presence or absence of GM-CSF (see Figure 2b) . pairs signed rank test. The addition of 10 IU/ml IL-2 + 10 IU/ml GM-CSF to the culture produced a cytotoxic activity similar to that produced by optimal doses of IL-2 (100 and 1000 IU/ml), P = NS. However the addition of GM-CSF to optimal doses of IL-2 does not increase the percentage of lysis generated. (b) NK activity measured as mean percentage of lysis of K562 line. The cytotoxic activity generated in the cultures does not significantly differ in the presence or the absence of GM-CSF. 
Effect of T cell depletions Clinical results
After receiving conditioning regimens and unmanipulated CD4 + and CD8 + T lymphocytes were undetectable by flow cytometry in the depleted cell suspensions.
PBSC on day 0, a mean of 2.02 ± 0.35 × 10 8 /kg and 2.14 ± 0.24 × 10 8 /kg LAK cells per patient were infused on Figure 3 shows the LAK activity generated after incubation with 10 IU/ml IL-2 plus GM-CSF by the whole cell day +1 and +8, respectively. Individual data regarding the number and lytic activity of the activated PBSC adminispopulation and after depletion of the CD4 + , CD8
+ and both CD4 + and CD8 + T cells, respectively. The depletion of each tered to each patient are shown in Table 2 . No patient developed significant toxicity related to LAK cells adminissubset significantly reduced the generation of LAK activity, but the magnitude of such reduction was different tration, and only one patient experienced chills during the infusion. depending on the subset depleted. When CD4 + T cells were absent, the mean LAK activity generated was significantly
The immunophenotype of the activated PBSC infused on day +1 is shown in Table 3 . The majority of the infused lower than that of the culture without depletion (30.2 ± 3.2 vs 39.8 ± 2.7; P = 0.04) but higher than that generated by cells expressed T lymphoid markers (CD2 and CD3). The proportions of NK cells as estimated by expression of CD8 + depleted cells (30.2 ± 3.2 vs 26.4 ± 3.1; P = 0.04).
The depletion of both CD4
+ and CD8 + T cells induced a CD16 and CD56 did not change with respect to values in PBSC before activation (data not shown). further decrease in LAK generation (17.8 ± 1.6). All these differences are statistically significant, suggesting that both
The total content of progenitors CD34 + and CFU-GM received by each patient, considering both the unmanipul-CD4 + and CD8 + cells have LAK generating potential, and are the main precursors in this model. ated and the activated cells is expressed in Table 2 . All Figure 4 shows the LAK activity in the peripheral blood of patients and controls during the first 60 days post-transplant. The mean lytic activity increased dramatically from 10 ± 2.6% on day 0 to 43.2 ± 2.1% on day +2, and it remains increased ranging from 21 to 42% during the entire period studied. No toxic effects derived from GM-CSF or IL-2 administration were noted.
One patient (PN 13) diagnosed with ALL with previous CNS involvement, relapsed in CNS at day +105 and in bone marrow at day +240. Five patients remain alive and disease-free with a median follow-up of 345 days (range: 210-580 days). The fact that a higher relapse rate is observed after autolostimualted with 10 IU/ml IL-2 + GM-CSF. The depletion of CD4 or CD8 gous than after allogeneic transplantation 15, 16 has focused subsets significantly reduced the generated LAK activity with respect to considerable attention on the activation of the immune systhe non-depleted population (P = 0.04). The depletion of both CD4 and CD8 T cells induced a further decrease in LAK generation (P = 0.04).
Discussion
tem as a way to eradicate residual neoplastic cells. 17 Such an immunotherapeutic approach has been explored by several groups with encouraging results, 1-3 and in particular, the infusion of IL-2 after autologous transplant is being used as part of many protocols in the clinical practice.
18-20
However, experiments conducted in mice revealed that the infusion of IL-2 alone was not sufficient to reduce the leukemic relapse after autoBMT, while the in vitro activation of the bone marrow followed by IL-2 infusion did improve the cure rate. 21 This can be due to the fact that both in animals and humans, the efficacy of immunotherapy depends on a very low tumor burden which is present only very early after transplant. At this time, the lack of IL-2-responsive cells in the circulation 6,7 makes impossible a lation. In this sense, much effort has been made to find a clinically applicable method for in vitro generation of LAK cells from bone marrow 22 and more recently, from patients reached hematologic trilineage engraftment. The course of their neutrophil and platelet recovery is shown in PBSC. 23, 24 As it has been demonstrated in these studies, LAK precursors are present in PBSC and can become acti- Table 2 . As shown, platelet recovery, considered as the day to reach more than 50 × 10 9 platelets/l, was delayed in four vated after incubation with standard doses of IL-2 (1000 IU/ml). Our results confirm these concepts using of the patients (PN 15, 16, 17 and 18) . However, none of them developed any hemorrhagic complications and all optimal doses of IL-2 (100 and 1000 IU/ml), and also establish the feasibility of generating LAK effectors from PBSC were free for platelet transfusion requirements on days +39, +16, +30 and +28, respectively.
by incubation with low-dose IL-2 + GM-CSF. Although GM-CSF is mainly a myeloid lineage growth therapy, probably due to the fact that LAK effectors in this model are mainly T cells and not NK cells. factor, a number of studies have revealed that it can also exert some influence on immune functions: in humans, In summary, our results demonstrate the feasibility of generating T-LAK effectors from PBSC from cancer GM-CSF augments the endogenously generated LAK cell function after autologous transplant, 13, 25 and in mice, it patients by activation with low-dose IL-2 + GM-CSF, as well as the effectiveness of the infusion of these LAK cells enhances the LAK activity after syngeneic transplant 26 and increases IL-2-induced LAK activity from murine splenoin combination with in vivo administration of GM-CSF and IL-2 in enhancing the cytolytic function after autologous cytes. 12 Interestingly, both in murine splenocytes and in our study, the cell population activated by low-dose ILtransplant. More patients and follow-up are necessary to evaluate the actual impact of this approach on the relapse 2 + GM-CSF is constituted by T cells and not by NK cells.
This finding can be explained by the fact that NK cells rate. express constitutively only the intermediate affinity p70 chain of the IL-2 receptor that requires high concentrations of IL-2 for activation. 27 In contrast, T lymphocytes have Acknowledgements GM-CSF receptors 28 CSF infusion, the generated LAK activity is predominantly mediated by a CD3 + CD16 − subset 25 with a high expression of the low affinity IL-2 receptor, whereas the NK function References is not affected. 25 Our results are in agreement with this evidence because the addition of GM-CSF to the cultures did Regarding the two main T cell subpopulations, our 
